Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Immunogenicity of a First-in-Human Mosquito Saliva Peptide Vaccine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03055000
Recruitment Status : Completed
First Posted : February 16, 2017
Results First Posted : August 3, 2020
Last Update Posted : August 11, 2020
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) )

Brief Summary:

Background:

Mosquitos carry diseases that cause major health problems and death worldwide. The AGS-v vaccine targets proteins in mosquito saliva. This may help prevent many mosquito-borne diseases. It might also reduce the lifespan of the mosquito that bites the vaccinated person.

Objective:

To see if the AGS-v vaccine is safe in humans and how it affects the immune system.

Eligibility:

Healthy adults ages 18-50

Design:

Participants will be screened another study.

Participants will be randomly assigned to get either the vaccine with a booster vaccine, the vaccine without the booster, or a placebo. These are given through a needle in the upper arm.

Participants will have visits that include medical history, physical exam, and blood and urine tests:

Baseline: They will get the vaccine and be monitored for 2 hours.

Follow-up visits 1 and 2 weeks after baseline.

Visit 3 weeks after baseline: They will get the booster and be monitored for 2 hours.

Follow-up visits 1 and 2 weeks after booster visit.

Visit 3-5 weeks after booster visit: This includes mosquito feeding. Mosquitos grown in the lab will be allowed to bite the arm. Blood will be drawn 4 times in the 3 hours after the feeding.

Phone follow-up a few days after the mosquito feeding.

After the feeding visit, 5 follow-up visits about every 2 months

Participants will keep a symptom diary for 7 days after each vaccine. They will record their temperature. They will measure any redness around the injection site. They will document and if possible photograph any mosquito bites they get.


Condition or disease Intervention/treatment Phase
Mosquito-Borne Disease Biological: AGS-v Biological: AGS-v + adjuvant Other: Placebo Phase 1

Detailed Description:

Mosquito-borne diseases continue to cause significant morbidity and mortality worldwide despite on-going control efforts. In 2015, there were >200 million cases of malaria worldwide, causing nearly half a million deaths, with most of the deaths occurring among children under the age of 5 years. Mosquitos also transmit arboviruses, including dengue, yellow fever, West Nile virus, chikungunya, Rift Valley fever, Japanese encephalitis, and Zika virus. The current new outbreak of Zika virus in Central and South America, as well as the Caribbean, serves as a reminder of how quickly these viruses can spread and how difficult they can be to control.

In this protocol we plan to perform a Phase I study of a novel universal mosquito-borne disease vaccine. Through modulation of the immune system after a mosquito feeding, this vaccine targets the vector saliva and may provide prophylaxis against multiple arboviral and protozoal diseases. In addition the vaccine potentially leads to a reduced mosquito lifespan after feeding therefore also reducing transmission of these diseases.

In this protocol we hope to demonstrate the safety of this vaccine similar to SEEK s other peptide based vaccines Flu-v and HIV-v that have been found to have very good safety profiles in previous Phase I trials. We also hope to demonstrate immunomodulation after a controlled clean Aedes aegypti mosquito feeding to demonstrate proof of concept efficacy of the vaccine. With the current rise of Zika in the Americas and the threat of local mosquito transmission in the U.S. and the rest of the world, a successful universal mosquito-borne disease vaccine offers the benefit of targeting this emerging disease as well as the many established infections such as dengue and malaria that make dealing with this newly emerging epidemic a challenge.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 49 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Other
Official Title: Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease Vaccine
Actual Study Start Date : February 15, 2017
Actual Primary Completion Date : December 28, 2018
Actual Study Completion Date : December 28, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Mosquito Bites

Arm Intervention/treatment
Experimental: AGS-v
AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21
Biological: AGS-v
AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21

Experimental: AGS-v with adjuvant
ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL)on Day 0 and on Day 21
Biological: AGS-v + adjuvant
ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL) on Day 0 and on Day 21

Placebo Comparator: Placebo
WFI (0.5mL) on Day 0 and Day 21
Other: Placebo
WFI (0.5mL) on Day 0 and Day 21




Primary Outcome Measures :
  1. AEs Grade 3 or Higher [ Time Frame: 1 year after vaccination (study duration) ]
    Grade 3 or higher adverse events identified within 1 year after 2 vaccinations 21 days apart.

  2. GM-CSF Cytokine Level as Measured by Luminex [ Time Frame: 21 days after last vaccination ]
    Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response

  3. IL-10 Cytokine Level as Measured by Luminex [ Time Frame: 21 days after last vaccination ]
    Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response

  4. IL-1B Cytokine Level as Measured by Luminex [ Time Frame: 21 days after last vaccination ]
    Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response

  5. IL-2 Cytokine Level as Measured by Luminex [ Time Frame: 21 days after last vaccination ]
    Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response

  6. IL-4 Cytokine Level as Measured by Luminex [ Time Frame: 21 days after last vaccination ]
    Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response

  7. IL-5 Cytokine Level as Measured by Luminex [ Time Frame: 21 days after last vaccination ]
    Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response

  8. Interferon-gamma Cytokine Level as Measured by Luminex [ Time Frame: 21 days after last vaccination ]
    Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response

  9. Number of Subjects With 1 or More Aes [ Time Frame: 1 year after vaccination (study duration) ]
    Percent of people with an AE

  10. Number of Subjects With 1 or More Grade 3 or Higher AE [ Time Frame: 1 year after vaccination (study duration) ]
    Percent of people with a Grade 3 or higher AE

  11. TNF-a Cytokine Level as Measured by Luminex [ Time Frame: 21 days after last vaccination ]
    Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response

  12. Total AGS-v Specific Immunoglobulin [ Time Frame: 21 days after last vaccination ]
    Total AGS-v specific immunoglobulin measured in serum 14 days after the first and/or second vaccination.


Secondary Outcome Measures :
  1. GM-CSF Cytokine Level as Measured by Luminex [ Time Frame: 60 days after Day 42 Mosquito Feeding ]
    Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response

  2. IL-10 Cytokine Level as Measured by Luminex [ Time Frame: 60 days after Day 42 Mosquito Feeding ]
    Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response

  3. IL-1B Cytokine Level as Measured by Luminex [ Time Frame: 60 days after Day 42 Mosquito Feeding ]
    Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response

  4. IL-2 Cytokine Level as Measured by Luminex [ Time Frame: 60 days after Day 42 Mosquito Feeding ]
    Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response

  5. IL-4 Cytokine Level as Measured by Luminex [ Time Frame: 60 days after Day 42 Mosquito Feeding ]
    Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response

  6. IL-5 Cytokine Level as Measured by Luminex [ Time Frame: 60 days after Day 42 Mosquito Feeding ]
    Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response

  7. Interferon-gamma Cytokine Level as Measured by Luminex [ Time Frame: 60 days after Day 42 Mosquito Feeding ]
    Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response

  8. Number of Adults Developed From 100 Eggs [ Time Frame: Day 42 Mosquito feeding ]
    Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination

  9. Number of Eggs Laid [ Time Frame: Day 42 Mosquito feeding ]
    Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination

  10. Number of Pupae Hatched of 100 Eggs [ Time Frame: Day 42 Mosquito feeding ]
    Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination

  11. Percent of Eggs That Developed Into Pupae [ Time Frame: Day 42 Mosquito feeding ]
    Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination

  12. Percent of Pupae That Developed Into Adults [ Time Frame: Day 42 Mosquito feeding ]
    Measurement of changes to Aedes aegypti mosquito life cycle post feeding on blood from participants after vaccination

  13. TNF-a Cytokine Level as Measured by Luminex [ Time Frame: 60 days after Day 42 Mosquito Feeding ]
    Interferon-gamma and other cytokine markers of Th1 and Th2 response measured in vitro from PBMCs incubated with AGS-v antigens as indicators of Th1 vs. Th2 response

  14. Total AGS-v Specific Immunoglobulin [ Time Frame: 60 days after Day 42 Mosquito Feeding ]
    Total AGS-v specific immunoglobulin measured in serum after the first and/or second vaccination.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

-INCLUSION CRITERIA:

  1. Healthy women and men who are greater than or equal to 18 and less than or equal to 50 years of age.
  2. Willingness to complete all study visits and comply with all study requirements.
  3. A male subject is eligible for the study if he agrees to practicing abstinence or using a condom with spermicide plus an acceptable form of contraception (see inclusion criteria 4) being used by any female partner from 4 weeks before study start to 12 weeks after the second vaccine administration.
  4. A female participant is eligible for this study if she is not pregnant or breast feeding and 1 of the following:

    • Of non-child bearing potential (i.e., women who have had a hysterectomy or tubal ligation or are postmenopausal, as defined by no menses in greater than or equal to 1 year).
    • Of childbearing potential but agrees to practice effective contraception or abstinence for 4 weeks prior to study initiation through 12 weeks after the second vaccine administration. Acceptable methods of contraception include a male partner who is sterile and is the sole sexual partner of the female participant or a male partner who uses a condom with spermicide plus 1 or more of the following: 1) implants of levonorgestrel; 2) injectable progestogen; 3) an intrauterine device with a documented failure rate of <1%; 4) oral contraceptives; and 5) double barrier method including diaphragm.
  5. Willing to have samples stored for future research (including genetic research).
  6. Agrees to abstain from alcohol intake for 24 hours prior to each study visit.
  7. Agrees to not donate blood or blood products throughout the study.

EXCLUSION CRITERIA:

  1. Participant has any underlying or current medical condition, which, in the opinion of the Investigator, would interfere with the participation in the study.
  2. Individual with body mass index (BMI) less than or equal to 18 and greater than or equal to 40.
  3. Participants who have a clinically significant (as determined by the PI) baseline Grade 1 or greater toxicity, or any Grade 3 or greater toxicity (regardless of clinical significance) by the toxicity table.
  4. Receipt of blood or blood products (including immunoglobulins) within 3 months prior to enrollment.
  5. Receipt of any unlicensed drug within 3 months or 5.5 half-lives (whichever is greater) prior to enrollment.
  6. Receipt of any unlicensed vaccine within 6 months prior to enrollment.
  7. Self-reported or known history of alcoholism or drug abuse within 6 months prior to enrollment, or positive urine/serum test for drugs of abuse at screening
  8. Self-reported or known history of psychiatric or psychological issues that require treatment and are deemed by the PI to be a contraindication to protocol participation.
  9. History of a previous severe allergic reaction with generalized urticaria, angioedema, anaphylaxis or anaphylactoid reaction.
  10. Any condition or event that, in the judgment of the PI, is a contraindication to protocol participation or impairs the volunteer's ability to give informed consent.
  11. Has a known allergy to any of the components of the vaccine.
  12. Has a history of severe immunization reaction.
  13. Has a severe allergic reaction to mosquito bites

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03055000


Locations
Layout table for location information
United States, Maryland
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
Layout table for investigator information
Principal Investigator: Matthew J Memoli, M.D. National Institute of Allergy and Infectious Diseases (NIAID)
  Study Documents (Full-Text)

Documents provided by National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) ):
Informed Consent Form  [PDF] April 2, 2018

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT03055000    
Other Study ID Numbers: 170059
17-I-0059 ( Other Identifier: NIAID )
First Posted: February 16, 2017    Key Record Dates
Results First Posted: August 3, 2020
Last Update Posted: August 11, 2020
Last Verified: December 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) ):
Mosquito-Borne Diseases
Universal Mosquito Vaccine
Mosquito Transmission
Vector Borne Viruses
Vaccine